Announcements
Sidley Represents Nektar Therapeutics in Its Sale of Its Manufacturing Facility and Reagent Supply Business
November 4, 2024
Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology.
The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).
Contacts
Capabilities
Suggested News & Insights
Sidley Represents Stonepeak on CA$1.215 Billion Sale of Its Interest in the KAPS Pipeline Project to KeyeraJune 17, 2026Delaware Court of Chancery Dismisses Stockholder Claims as Derivative, Unripe, and UntimelyJune 16, 2026Sidley Represents Yum China Holdings in US$1.2 Billion Acquisition of Pizza Hut Brand in Mainland ChinaJune 16, 2026Sidley Represents Wafra in US$1.9 Billion Acquisition of NavitasJune 12, 2026Delaware Supreme Court Affirms Limits on Hypothetical Bylaw ChallengesJune 11, 2026Sidley Represents Compactor Rentals of America in Acquisition of Tower Compactor RentalsJune 11, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory